CHICAGO, July 31, 2025--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. ("Meitheal"), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization ...
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic ...
Meitheal Pharmaceuticals recently launched two new generics. The company released alprostadil injection 500 mcg/ml single-dose vials to the U.S. market, where only an ampoule form is offered. The ...
XTMAB-16 is a clinical-stage anti-TNFα antibody anticipated to enter Phase 2 trial in 2023 Preclinical data for XTMAB-16 demonstrated an ability to reduce activation of an inflammatory pathway ...
Xentria’s bid to find a new use for TNF inhibitors has landed it with $45 million in the bank. Building on evidence that Remicade improves outcomes in a lung disease, Xentria has persuaded Meitheal ...
Protein-bound paclitaxel formulation is used to treat various types of cancer, including metastatic breast cancer and metastatic adenocarcinoma of the pancreas More than 168,000 people live with ...
Meitheal Pharmaceuticals said it has acquired the North American rights to a novel antibiotic for treating complicated urinary tract infections. The company said yesterday it's buying Contepo ...
Meitheal Pharmaceuticals has gotten federal approval for a new kind of antibiotic for use on hospitalized patients with urinary tract infections, a major step in the Chicago biopharma company's ...
Meitheal has expanded its biosimilars portfolio with an exclusive commercial licensing agreement with its parent company, Hong Kong King-Friend Industry Co., to market and distribute three biosimilars ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results